Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $750.00 | 1 | 54.0% |
| Education | $384.98 | 4 | 27.7% |
| Food and Beverage | $254.47 | 4 | 18.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. | $750.00 | 1 | $0 (2023) |
| Janssen Biotech, Inc. | $384.98 | 4 | $0 (2024) |
| ABBVIE INC. | $120.62 | 1 | $0 (2023) |
| Amgen Inc. | $89.00 | 1 | $0 (2017) |
| Boston Scientific Corporation | $28.59 | 1 | $0 (2024) |
| Sun Pharmaceutical Industries Inc. | $16.26 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $226.59 | 3 | Janssen Biotech, Inc. ($198.00) |
| 2023 | $965.61 | 3 | Arcutis Biotherapeutics, Inc. ($750.00) |
| 2022 | $91.99 | 1 | Janssen Biotech, Inc. ($91.99) |
| 2020 | $16.26 | 1 | Sun Pharmaceutical Industries Inc. ($16.26) |
| 2017 | $89.00 | 1 | Amgen Inc. ($89.00) |
All Payment Transactions
9 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/06/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 09/20/2024 | Boston Scientific Corporation | — | Food and Beverage | In-kind items and services | $28.59 | General |
| 04/11/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Immunology | ||||||
| 10/25/2023 | ABBVIE INC. | RINVOQ (Biological) | Food and Beverage | In-kind items and services | $120.62 | General |
| Category: IMMUNOLOGY | ||||||
| 06/06/2023 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Education | In-kind items and services | $94.99 | General |
| Category: Immunology | ||||||
| 01/31/2023 | Arcutis Biotherapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| 09/07/2022 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Education | In-kind items and services | $91.99 | General |
| Category: Immunology | ||||||
| 10/22/2020 | Sun Pharmaceutical Industries Inc. | ILUMYA (Biological) | Food and Beverage | Cash or cash equivalent | $16.26 | General |
| Category: Dermatology | ||||||
| 01/25/2017 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $89.00 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,608 | 2,200 | $407,522 | $111,740 |
| 2022 | 9 | 1,494 | 2,053 | $305,603 | $76,186 |
| 2021 | 9 | 1,460 | 2,164 | $297,887 | $74,680 |
| 2020 | 9 | 1,503 | 2,169 | $301,829 | $65,480 |
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 392 | 529 | $134,895 | $46,442 | 34.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 283 | 306 | $52,632 | $15,756 | 29.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 141 | 164 | $42,804 | $13,538 | 31.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 272 | 310 | $31,930 | $10,767 | 33.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 127 | 152 | $57,760 | $9,537 | 16.5% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 190 | 236 | $45,076 | $8,718 | 19.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 21 | 21 | $8,190 | $2,586 | 31.6% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 129 | 424 | $22,896 | $2,033 | 8.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 34 | 39 | $7,995 | $1,471 | 18.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $3,344 | $891.03 | 26.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 614 | 881 | $90,743 | $30,066 | 33.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 251 | 272 | $46,784 | $16,714 | 35.7% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 154 | 189 | $71,820 | $11,973 | 16.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 218 | 283 | $54,053 | $10,806 | 20.0% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 50 | 64 | $13,120 | $2,111 | 16.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 149 | 305 | $16,470 | $1,364 | 8.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 32 | 32 | $5,632 | $1,324 | 23.5% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 15 | 16 | $4,176 | $948.37 | 22.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,805 | $880.24 | 31.4% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 726 | 1,080 | $111,240 | $36,807 | 33.1% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 159 | 189 | $71,820 | $12,453 | 17.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 155 | 158 | $27,176 | $9,444 | 34.8% |
| 17000 | Destruction of skin growth | Office | 2021 | 179 | 230 | $43,930 | $8,090 | 18.4% |
| 11103 | Tangential biopsy of additional skin lesion | Office | 2021 | 49 | 61 | $12,505 | $2,295 | 18.3% |
| 99202 | New patient outpatient visit, total time 15-29 minutes | Office | 2021 | 43 | 43 | $7,568 | $1,808 | 23.9% |
About Dr. John Murray, MD
Dr. John Murray, MD is a Dermatology healthcare provider based in Durham, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043256258.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Murray, MD has received a total of $1,389 in payments from pharmaceutical and medical device companies, with $226.59 received in 2024. These payments were reported across 9 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($750.00).
As a Medicare-enrolled provider, Murray has provided services to 6,065 Medicare beneficiaries, totaling 8,586 services with total Medicare billing of $328,086. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Practice Information
- Specialty Dermatology
- Location Durham, NC
- Active Since 06/22/2006
- Last Updated 07/08/2007
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1043256258
Products in Payments
- TREMFYA (Drug) $384.98
- RINVOQ (Biological) $120.62
- ILUMYA (Biological) $16.26
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Durham
Dr. Jeffrey Scales, M.d, M.D
Dermatology — Payments: $422,903
Negar Foolad
Dermatology — Payments: $76,225
Dr. Russell Hall, M.d, M.D
Dermatology — Payments: $44,389
Brooke Jackson, Md, MD
Dermatology — Payments: $39,243
Dr. Amy Drumheller, M.d, M.D
Dermatology — Payments: $10,765
Ms. Julie Dodge, Pa-C, PA-C
Dermatology — Payments: $8,189